C4 Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CCCC and other ETFs, options, and stocks.About CCCC
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system.
CEOAndrew J. Hirsch
CEOAndrew J. Hirsch
Employees110
Employees110
HeadquartersWatertown, Massachusetts
HeadquartersWatertown, Massachusetts
Founded2015
Founded2015
Employees110
Employees110
CCCC Key Statistics
Market cap236.47M
Market cap236.47M
Price-Earnings ratio-1.45
Price-Earnings ratio-1.45
Dividend yield—
Dividend yield—
Average volume1.69M
Average volume1.69M
High today$2.61
High today$2.61
Low today$2.40
Low today$2.40
Open price$2.49
Open price$2.49
Volume1.06M
Volume1.06M
52 Week high$4.53
52 Week high$4.53
52 Week low$1.09
52 Week low$1.09
Stock Snapshot
C4 Therapeutics(CCCC) stock is priced at $2.45, giving the company a market capitalization of 236.47M. It carries a P/E multiple of -1.45.
On 2025-12-15, C4 Therapeutics(CCCC) stock moved within a range of $2.40 to $2.61. With shares now at $2.45, the stock is trading +2.1% above its intraday low and -6.1% below the session's peak.
Trading volume for C4 Therapeutics(CCCC) stock has reached 1.06M, versus its average volume of 1.69M.
Over the past 52 weeks, C4 Therapeutics(CCCC) stock has traded between a high of $4.53 and a low of $1.09.
Over the past 52 weeks, C4 Therapeutics(CCCC) stock has traded between a high of $4.53 and a low of $1.09.
Analyst ratings
100%
of 8 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own CCCC. This list is generated using Robinhood data, and it’s not a recommendation.